Left Menu
Development News Edition

Britain benefits from copy cat biotech drugs’ use, leaves US behind

In the United States, the key battleground is still over copycat Remicade, which has sparked a high-profile legal fight between J&J and Pfizer.

Britain benefits from copy cat biotech drugs’ use, leaves US behind
In the United States, the key battleground is still over copycat Remicade, which has sparked a high-profile legal fight between J&J and Pfizer.(Image credit: Reuters)

Cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds (USD 113 million) a year, experts said on Wednesday.

The rapid adoption of two so-called biosimilar forms of rituximab from Celltrion and Novartis has been accompanied by discounts of 50-60 percent as the National Health Service (NHS) has used tenders to bring down costs.

The situation contrasts sharply with the United States, where regulators have lagged Europe in approving biosimilars while a complex system of rebates offered to insurers by original-brand drugmakers has created barriers to use.

The US logjam prompted Food and Drug Administration (FDA) Commissioner Scott Gottlieb to complain of "rebating mischief" and a "rigged payment scheme" in a speech here on March 7.

Biological drugs such as Rituxan, a USD 7 billion-a-year seller, are complex molecules made inside living cells.

Copies of some biotech medicines have been on sale in Europe for more than a decade, but it is only now that patents are starting to expire on big-selling antibody treatments for cancer and other serious diseases, with the pace expected to accelerate.

Only this month Merck launched Europe's first biosimilar copy of Roche's breast cancer antibody drug Herceptin in Britain under a deal with Samsung Bioepis. More Herceptin copies are set to follow this year.

A biosimilar version of AbbVie's rheumatoid arthritis drug Humira — the world's biggest-selling medicine — is also expected later this year, with biosimilar Avastin, another Roche cancer drug, expected in 2019.

Britain's NHS has estimated that biosimilars could save it up to 300 million pounds a year. Jatinder Harchowal, chief pharmacist at the Royal Marsden hospital and one of the coordinators of the UK's push for biosimilar use, believes the scale of discounts achieved so far mean the savings could be even higher.

"These are large figures. Without compromising clinical effectiveness, this is a big saving that can be reinvested back into the NHS," he told a news briefing.

The uptake of biosimilar rituximab has been significantly faster than with the first antibody biosimilar, a copy of Johnson & Johnson and Merck's Remicade for arthritis, which Harchowal attributed to tendering and growing doctor confidence.


In the United States, the key battleground is still over copycat Remicade, which has sparked a high-profile legal fight between J&J and Pfizer.

Pfizer, a major biosimilars player and supplier of innovative drugs, has sued J&J over its Remicade contracts with health insurers, arguing that they are anti-competitive and block sales of Pfizer's new biosimilar.

Pfizer contends that J&J is offering discounts on Remicade in exchange for essentially excluding Pfizer's drug from insurance coverage, keeping it out of the hands of doctors and patients. J&J says Pfizer's suit is without merit.

Jenny Alltoft, Pfizer's global head of biosimilars, told Reuters that a tilted playing-field against biosimilars was a threat not only to Pfizer but also to the wider US healthcare system, which is struggling with spiralling costs.

"Pfizer wanted to shine a light on this with the lawsuit so that it doesn't become common practice, because if it does, then the US will never get the benefit that biosimilars could offer in terms of patient access and healthcare savings," she said during a visit to London.

The tussles in the biosimilars market are a growing focus for investors, with soaring valuations for some pioneers in the field, such as South Korea's Celltrion, and worries about the long-term sales threat to makers of original drugs, such as Roche and AbbVie.

Consensus forecasts from analysts suggest that combined sales of Roche's Rituxan, Herceptin and Avastin will halve over the next five years, leaving a gap the Swiss group must fill with new drugs for cancer, multiple sclerosis and haemophilia.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)



Hyderabad Encounter: A sentiment analysis of public mood on day of encounter

Sentiment analysis of twitter users revealed that they showered salutes on Hyderabad police for eliminating alleged gang rapists of the veterinary doctor but only a few believe in cops version of successive events leading to encounter....

Hyderabad Encounter: Time to review modern judiciary and restore people’s confidence

Its probably for the first time in the history of independent India, the parliamentarians, chief ministers and ministers in the Union and State governments are openly supporting an encounter. This indicates the people from top to bottom hav...

What happens to your outstanding loans if the bank falls?

... ...

Time for a change! Innovations to stop the growing plastic pollution

As the planet is drowning in plastic pollution, many new innovative approaches and solutions have emerged to effectively deal with the menace....


Latest News

Merkel expects Russia to cooperate in dispute over killing of Georgian

Chancellor Angela Merkel said she had told Russian President Vladimir Putin in bilateral talks in Paris on Monday that Germany expects Russia to provide information for an investigation into the murder of a Georgian man in Berlin.German pro...

WRAPUP 1-U.S. negotiators set to make last-minute trip to Mexico to pin down USMCA deal

The Trump administration, Mexico and U.S. Democrats on Monday closed in on a deal for labor-related changes to a languishing North American trade pact that may soon allow it to proceed to a vote, as the window for passage this year quickly ...

Ravens QB Jackson limited with quad injury

Theres no stopping Baltimore Ravens quarterback Lamar Jackson this season, but on a short week his quadriceps injury could keep him out of practice. Jackson was listed as limited on Monday by the Ravens, who did not practice but were requir...

Putin says Moscow could appeal Russia sports ban

Russian President Vladimir Putin said on Monday Moscow had grounds to appeal a decision by the World Anti-Doping Agency WADA to bar Russia from major sporting events, a move he said violated the Olympic charter.Russia was banned from the wo...

Give Feedback